Currently the main use of pharmaceutical databases are divided into two main categories, one is free pharmaceutical databases, and the other is commercial comprehensive pharmaceutical databases. The essence of pharmaceutical databases is to enable users to search for the information they want in a short period of time on a single website at a glance, so comprehensiveness, accuracy and timeliness are the main indicators of this type of databases.
First of all, the free medical database, large and small more, but the real user volume, to achieve a certain frequency of use, we recommend three of the most comprehensive:
①: DrugBank database, which is the University of Alberta (University of Alberta), Canada, researchers will be a combination of detailed drug data and comprehensive drug target DrugBank contains information on 500,000 drugs, including 2,653 approved small molecule drugs, 1,417 approved biotechnology (protein/peptide) drugs, 131 nutraceuticals and 6,451 experimental drugs.
②: pharnexcloud, who is currently the Chinese interface pharmaceutical database with a high degree of openness, contains a large amount of integrated information on the global drug R&D pipeline, the progress of review and approval, global clinical trials, Chinese clinical trials, drug bidding, collective purchasing, consistency evaluation, and so on.
③: ClinicalTrials, which is a web-based resource that provides patients, their family members, healthcare professionals, researchers, and the public with easy access to information about public*** and privately-supported clinical research on a wide range of diseases and conditions. The site is maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH), and the U.S. National Library of Medicine provides resources for exploring 422,494 studies in all 50 states and 221 countries/territories. Note: All information and related studies are for informational purposes only and have not been rated by relevant government agencies.
Free databases are limited in their relevance and depth of data, and they do not have the human and time costs of commercial databases to clean, organize, and maintain the data.
Commercial pharmaceutical databases are often high-value database representatives. Commercial pharmaceutical database is characterized by powerful features not only to academic information to integrate processing, but also to analyze the full life cycle of the drug data, competing drug sales details, competing enterprises bidding, investment and financing, centralized purchasing information; in addition to real-time tracking of the latest information on the product pipeline to achieve real-time adjustments in the strategic direction, to prevent the waste of resources to do useless work. Now the commercial database can be said to be the essential database for pharmaceutical enterprises. The author of the domestic pharmaceutical companies mainly use the commercial pharmaceutical database (while comparing two foreign databases) to give you a list.
Pharnexcloud enterprise version of Pharnexcloud
Data comprehensiveness: ★★★★★
Operating company: Pharnexcloud digital science and technology
Online time: 2020
Number of databases: 218
Products composed of: drug research and development library group, listed drug library group, drug sales library group, Market Information Database Group, Consistency Evaluation Database Group, API Database Group, Medical Device Database Group, Production and Inspection Database Group, Rational Use of Drugs Database Group, Pharmaceutical Literature and other ten sections.
Data sources: national drug regulatory agencies, experimental research, academic conference reports, literature and journals, heterogeneous resources, corporate announcements of national health institutions, medical news magazines, network information, patents, associations and societies.
Data features: data collection in nearly 80 mainstream countries, monitoring of 100,000+ global pharmaceutical data sources, data amplification model algorithms involving demographics, economics, morbidity, distribution of healthcare resources, and other types of characteristic parameters.
Value-added services: ① Specialized docking demand, team problem solving. ② Salon, lecture tour, summit, project trading, demand docking and other activities to support the ability to join their medicine fusion circle ecosystem.
Pros: comprehensive coverage of the pharmaceutical field of the whole industry chain links, the total amount of data, data sources, professional reports, data algorithms, the results of the show are doing very well.
Disadvantages: compared with the world's top cortellis, informa, etc., pharnexcloud's data display results relevance there is still obvious room for progress.
pharnexcloud pharmaceutical database later on, the progress is very fast, in recent years gradually become the domestic pharmaceutical enterprises choose more pharmaceutical database, because of its comprehensive product features and data comprehensiveness has been more and more recognized, I hope to maintain this rate of progress.
Pharmaceutical Intelligence
Comprehensive Recommendation Index: ★★★★☆
Operating Company: Chongqing Kangzhou Data
Launch Time: 2009
Product Composition: consists of R & D, consistency, production, listing, market, medicine, medication, medication, Chinese herbal medicines, devices and other nine sections.
Data sources: regional organizations, information, corporate announcements and reports, medical conferences, company annual reports, medical and health institutions, medical journals, patents, trademarks, technical implementation documents, academic conferences, technical reports, scientific and technological journals, and so on.
Number of databases: 172
Retrieval methods, function points, underlying data architecture, interface display: largely consistent with insight, Pharnexcloud database.
Advantages: drug synthesis report, review, clinical data are doing quite well. And only this one launched cosmetics, food database.
Weaknesses: pharmaceutical sales data is not mature enough in the initial stage, and the amount of global data is relatively small. (Drug sales data is the most important for the research of drug projects, sales analysis of competing products, and the formulation of sales strategy goals). The number of innovative drugs included in the list needs to be improved.
Pharma Magic
Comprehensive recommendation index: ★★★★☆
Operating company: Beijing Huabin Lixing
Launch date: 2013
Number of databases: 49
Products: five sections: Capital Insight, New Drugs, Clinicals, Data, and Market Insight.
Data Sources: Laboratory Research, Internal Conferences, Professional Reports, Patents, Trademarks, Technical Implementation Documents, Academic Conferences, Technical Reports, Scientific Journals, Literature, Textbooks, Regional Institutions, Information, News, Company Annual Reports, and more.
Product highlights: Capital Insights and Innovative Drugs sections are doing very well, and both are industry leaders in their field.
Charges: unit price is on the high side in China
Pros: investment and financing section, visualization of disease mapping and target integration, review, clinical and other data to do a full correlation, the newly launched NextMed section has a certain leading edge, and its investment and financing section is doing very well.
Weaknesses: the overall amount of data is small, drug development is also only deciphered more than 30,000 drugs, compared to similar products lost some of the functionality of the section, global data is not rich enough. Sales data module is available, but very closed, without any publicity, the industry does not understand its specifics.
Pharmaceutical magic as innovative drugs and pharmaceutical investment and financing database is currently one of the domestic users deposited more database, but its product features are too closed, has become its own wall.
Pharmaceutical ferry
Comprehensive recommendation index: ★★★★☆
Operating company: pharmaceutical ferry Jingwei information technology
Launch time: 2013
Number of databases: 132
Product composition: by the global drug, global device, investment ecology, clinical research, patent literature, policies and regulations, the world drug question, Data Customization eight sections.
Data sources: laboratory research, internal meetings, professional reports, patents, trademarks, technical implementation documents, academic conferences, technical reports, scientific and technical journals, online databases, online thesaurus, e-book libraries, regional organizations, information, corporate announcements and reports, and medical conferences.
Advantages: Its drug R&D information is well related to multiple libraries such as domestic review and clinical, and its hierarchical structure, labeling and interface are quite well done. The subtle labels for biologics, chemical drugs, etc. are individually optimized.
Weaknesses: currently there is no drug sales data, clinical, listed drug analysis and other data collection is relatively weak, the overall amount of data in the industry is weak.
As one of the oldest pharmaceutical databases in China, Yudu takes global R&D data as its core and focuses on the development of consulting business. The lack of sales data and its core section data, resulting in its data business has only been a low price in its consulting business to do support.
Mine
Comprehensive Recommendation Index: ★★★★☆
Operating Company: Guangzhou Standard Pharmaceutical Information
Launch Time: 2010
Number of Databases: 72
Products Composition: Pharmaceutical Sales (Multi-Level Patterns, Hospitals, Retail), Evaluation Progress, Listed Drugs, Clinical Trials, and Winning Bids Data, Global new drug R&D, global patents, project progress of the seven sections
Product features: domestic pharmaceutical sales data leader, its hospital sales data based on the "three major terminals and six markets", stratified sampling of multi-level hospitals enlarged to the whole country. Urban public hospitals, county-level public hospitals, brick-and-mortar pharmacies, online pharmacies, urban community health centers, township health centers and other types of dimensions are available.
Advantages: Southern Institute background, hospital sales data algorithms and R & D data are doing very well. The six patterns are second to none in the country. Recently on-line exclusive e-commerce category data, although the industry is still disputing the credibility of e-commerce data, but after all, the first step out of this step.
Weaknesses: the comprehensiveness is relatively weak, the global data other than sales data, R & D data, approval data is relatively low priority, the version has not been a major progress.
Minet Pharmaceutical Database South Institute background its hospital sales section has one of the widest coverage, but other sections are relatively weak.
The Clove Park Insight
Comprehensive Recommendation Index: ★★★★★☆
Operating Company: Hangzhou Guanlan Network
Online Time: 2013 Insight (2006 HQ)
Products Composition: Clinical Trials, Declaring Progress, Drug Library, Listed Products, Pharmaceutical Companies, Bidding, Consistency Evaluation, Pharmaceutical News, Biological Products, Global Data and other ten sections constitute.
Data sources: internal meetings, professional reports, patents, trademarks, online databases, online dictionaries, e-book libraries, heterogeneous resource **** enjoyment platform, knowledge base, regional organizations, information, corporate announcements and reports, medical conferences, news and information.
Product features: its interface small function development is rich especially the application of small icons in the domestic UI design is good, differentiated from similar products.
Search method, function points, underlying data architecture, interface display: largely consistent with the Pharmaceutical Intelligence Database.
Pros: search experience, UI interface small features, timeline, registration data, domestic drug review, marketing approvals of these domestic data in a very good job.
Weaknesses: less market and sales-related data, global R & D data is in its infancy (global drug R & D data is very important for pharmaceutical companies can be said to be the wind vane of the pharmaceutical industry, the importance of the global drug landscape, drug project research, the development of strategic direction of corporate development is self-evident)
Insight, as a typical representative of the old pharmaceutical database, is backed by the Ding Xiangyuan Group. Representative, backed by the tree of the Ding Xiangyuan Group, one of the databases with more users deposited in China at present, but because of the late start of its drug R&D data section, drug market and sales data, which affects its overall advantages.
Shanghai Institute of Medical Technology PDB
Index of comprehensive recommendation: ★★★★
Operating company: Shanghai Numerical Health Pharmaceutical Technology
Online: 2011
Number of databases: 31
Products: divided into two databases of drug synthesis and monitoring of new drug R&D; the drug synthesis database contains the domestic The drug synthesis database contains five sections: domestic market, market segments, global market, domestic industrial production, and enterprise economic operation; the new drug R&D monitoring database contains five sections: global R&D, Chinese R&D, consistency evaluation, enterprise competition, and variety screening analysis.
Data sources: patents, trademarks, technical implementation documents, academic conferences, technical reports, scientific and technical journals, literature, textbooks, regional organizations, information, news information, company annual reports, pjb, etc.
Advantages: Ministry of Industry and Information Technology background high visibility of the originator of the domestic pharmaceutical database, review, clinical and other data have a good correlation between the display; the newly launched RPDB retail board has a clear advantage to improve; RAS pharmaceutical prescription analysis system has a certain degree of exclusivity.
Weaknesses: relatively low data comprehensiveness, part of the industrial data is slow to update, UI design is too traditional. PDB as one of the country's oldest pharmaceutical databases, the global drug R & D data collection is in its infancy, perhaps the underlying architectural design issues single open a CPM (new drug R & D monitoring database) resulting in some of the correlation between its poor.
Corevision cortellis
Comprehensive Recommendation Index: ★★★★☆
Product Composition: Cortellis database contains Cortellis Competitive Intelligence, Cortellis Early Drug Discovery, CMC, Generic Medicines, APIs, Systems Biology Metacore and so on. Cortellis Competitive Intelligence, Disease Briefs, Regulatory Information, News, Drug Discovery Information, etc.
Data sources: drug regulatory agencies, news magazines, online information, journals, academic reports, patents, trademarks, annual reports, etc.
Retrieval mode, function points, underlying data architecture: these three dimensions and informa database is basically the same, just style display style is different.
Advantages:? In the display results correlation, professional reports, data dimensions are done very well.
Cons: ? Lack of systematic drug sales data, quite a few lags and a few errors in monitoring the pipeline of Chinese companies, lack of data analysis such as China's Drug Administration.
Cortellis pharmaceutical database is currently one of the world's leading pharmaceutical databases in the field of pharmaceuticals, because in the country because of its lack of suitability compared to the proportion of people who use it is not so much.
Informa
Informa Informa
Comprehensive recommendation index: ★★★★★☆
Products: Biomedtracker, Pharmaprojects, Sitetrove, Trialtrave, Datamonitor Healthcare, In Vivo, Medtech Insight, Pink Sheet, and Scrip consist of multiple sections.
Data sources: drug regulatory agencies, healthcare organizations, news magazines, online information, journals, academic reports, patents and trademarks, company annual reports, search engines, academic conferences, etc.
Retrieval mode, function point, underlying data structure: these three dimensions and cortellis database is basically the same, just style display style is different, more in line with the national habit of use.
Advantages: can be synthesized to calculate the drug approval pass rate, data update history, in the news data traceability, display results correlation, data dimensions are doing well.
Disadvantages: no sales data, no generic drug information, lack of interpretation of China's Drug Administration data, lagging tracking of Chinese companies' pipelines;
Informa Pharmaceutical Database is currently one of the world's mainstream pharmaceutical databases, and its Pharmaprojects section Pharnexcloud's 'Global Drug R&D The Pharmaprojects section of Pharnexcloud 'global drug development' is compared by customers, because of the price and the lack of domestic approval and other data, so the occupancy rate is low, the current main customer population in the country for the university-based.
A*** wrote the evaluation of the current domestic main use of nine mainstream databases, two foreign pharmaceutical databases. Each database has its own characteristics, according to their own situation for you to choose.